Torii

FDA clears Kyowa Kirin’s skin lymphoma therapy Poteligeo

Kyowa Kirin has been selling Poteligeo in Japan since 2012, and the company says its approval in the US is a key milestone on the path to becoming a  global specialty ... Sales of Poteligeo in Japan were 1.9bn yen ($17m) in fiscal 2017, and are

New cancer drugs can’t quite plug the revenue hole at AZ

Overall sales fell 5% to $10.33bn, however, thanks to generic competition taking another chunk out of cholesterol drug Crestor (rosuvastatin) sales, particularly in Europe and Japan. ... its launch in Japan, while Tagrisso grew 82% to $760m on the back

Happy 70th birthday NHS: the next 70 need to be very different

This still leaves it in line with an unweighted EU-15 average of 9.8% of national income, but far behind countries such as the US (16.9%), Japan (11.2%),

Roche’s Tamiflu successor hits the mark in complicated flu

is already on the market in Japan, where its originator Shionogi won approval earlier this year as Xofluza.

The NHS at 70: celebrations, renewed reforms and difficult choices

This still leaves it in line with an unweighted EU-15 average of 9.8% of national income, but far behind countries such as the US (16.9%), Japan (11.2%),

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]